Filtered By:
Condition: Diabetes
Drug: Diovan
This page shows you your search results in order of date.
Order by Relevance | Date
Total 14 results found since Jan 2013.
Late-Breaking Data from Pivotal Phase 3 PRECISION Study Demonstrates Significant and Sustained Effect of Aprocitentan on Lowering Blood Pressure for Patients with Difficult-to-Control Hypertension
RARITAN, NJ, November 7, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson, in collaboration with Idorsia Ltd, today announced results from the Phase 3 PRECISION study, which found aprocitentan, an investigational, novel dual endothelin receptor antagonist (ERA), significantly reduced blood pressure (BP) and maintained the effect for up to 48 weeks when added to standardized combination background antihypertensive therapy in patients with difficult-to-control hypertension (sometimes referred to as resistant hypertension). These data were presented as a Late-Breaking Science presentation during the Amer...
Source: Johnson and Johnson - November 7, 2022 Category: Pharmaceuticals Source Type: news
Cardiovascular outcomes at recommended blood pressure targets in middle-aged and elderly patients with type 2 diabetes mellitus compared to all middle-aged and elderly hypertensive study patients with high cardiovascular risk.
CONCLUSION: In the high-risk hypertensive patients of the VALUE trial achieving more frequently BP <140/90 mmHg, but not <130/80 mmHg, showed principally the same protective effect on overall and cause-specific cardiovascular outcomes in patients with diabetes mellitus and in the general high-risk hypertensive population.
PMID: 33403890 [PubMed - as supplied by publisher]
Source: Blood Pressure - January 8, 2021 Category: Hematology Tags: Blood Press Source Type: research
Cardiovascular outcomes at recommended blood pressure targets in middle-aged and elderly patients with type 2 diabetes mellitus and hypertension.
CONCLUSION: In mostly elderly high-risk hypertensive patients with type 2 diabetes mellitus participating in the VALUE trial, achieving more frequently BP <140/90 mmHg showed a marked protective effect on overall and all cause-specific cardiovascular outcomes. This was not the case for a more frequent achievement of the more intensive BP target, i.e. <130/80 mmHg.
PMID: 33403886 [PubMed - as supplied by publisher]
Source: Blood Pressure - January 8, 2021 Category: Hematology Tags: Blood Press Source Type: research
Does Neprilysin Inhibition Potentiate or Minimize the Adverse Effects of Glucagon-Like Peptide-1 Receptor Agonists in Chronic Heart Failure?
Heart failure and diabetes commonly coexist, and therefore, drugs that favorably influence the natural history of each of these two disorders are likely to be prescribed together.1 In patients with type 2 diabetes, glucagon-like peptide-1 (GLP-1) receptor agonists decrease the risk of major adverse cardiovascular events,2,3 and liraglutide is approved to reduce cardiovascular death, nonfatal myocardial infarction and nonfatal stroke.4 Analogously, in patients with chronic heart failure and a reduced ejection fraction, neprilysin inhibition has been shown to decrease the risk of cardiovascular death and hospitalization for ...
Source: Journal of Cardiac Failure - January 3, 2018 Category: Cardiology Authors: Milton Packer Tags: Editorial Source Type: research
International Variation in Outcomes Among People with Cardiovascular Disease or Cardiovascular Risk Factors and Impaired Glucose Tolerance: Insights from the NAVIGATOR Trial Epidemiology
BackgroundRegional differences in risk of diabetes mellitus and cardiovascular outcomes in people with impaired glucose tolerance are poorly characterized. Our objective was to evaluate regional variation in risk of new‐onset diabetes mellitus, cardiovascular outcomes, and treatment effects in participants from the NAVIGATOR (Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research) trial.Methods and ResultsNAVIGATOR randomized people with impaired glucose tolerance and cardiovascular risk factors or with established cardiovascular disease to valsartan (or placebo) and to nateglinide (or placebo) with a ...
Source: JAHA:Journal of the American Heart Association - January 13, 2017 Category: Cardiology Authors: Harumi Higuchi dos Santos, M., Sharma, A., Sun, J.-L., Pieper, K., McMurray, J. J. V., Holman, R. R., Lopes, R. D. Tags: Cardiovascular Disease, Diabetes, Type 2, Risk Factors Original Research Source Type: research
Sacubitril/Valsartan Reduces Serum Uric Acid Level, an Independent Predictor of Adverse Outcomes in HFrEF: Results From PARADIGM-HF
We examined the association between UA level and outcomes in patients with HFrEF and the effect of sacubitril/valsartan on UA concentrations in patients in PARADIGM-HF. Methods: The association between UA and the primary composite outcome of cardiovascular (CV) death or HF hospitalization, its components and all-cause mortality was examined among 8213 patients using quintiles of UA (Q1:
Source: Journal of Cardiac Failure - July 23, 2016 Category: Cardiology Authors: Ulrik M. Mogensen, Pardeep S. Jhund, Lars K øber, Margaret F. Prescott, Martin P. Lefkowitz, Jean-Lucien Rouleau, Scott D. Solomon, Karl Swedberg, Michael R. Zile, Milton Packer, John J.V. McMurray Source Type: research
Predictors of cardiac morbidity in diabetic, new-onset diabetic and non-diabetic high-risk hypertensive patients: The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial.
Authors: Aksnes TA, Kjeldsen SE, Rostrup M, Holzhauer B, Hua TA, Julius S
Abstract
Diabetic and new-onset diabetic patients with hypertension have higher cardiac morbidity than patients without diabetes. We aimed to investigate whether baseline predictors of cardiac morbidity, the major constituent of the primary endpoint in the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial, were different in patients with diabetes and new-onset diabetes compared to patients without diabetes. In total, 15,245 high-risk hypertensive patients in the VALUE trial were followed for an average of 4.2 years. At baselin...
Source: Blood Pressure - February 14, 2016 Category: Hematology Tags: Blood Press Source Type: research
No evidence for a J-shaped curve in treated hypertensive patients with increased cardiovascular risk: The VALUE trial.
In conclusion, patients in BP strata ≥ 150/90 mmHg, but not patients in BP strata < 130/70 mmHg, were at increased risk for adverse outcomes in this hypertensive, high-risk population. Although benefit in preventing MI in relation to preventing stroke levels off for the lowest BPs, these data provide no support for a J-curve in the treatment of high-risk hypertensive patients . The increase in the ratio of MI to stroke with lower DBP indicates target organ heterogeneity in that the optimal on-treatment DBP for cerebroprotection is below that for cardioprotection.
PMID: 26511535 [PubMed - in process]
Source: Blood Pressure - February 14, 2016 Category: Hematology Tags: Blood Press Source Type: research
Walking reduces heart disease in people at risk
Conclusion
This study of adults at high risk of type 2 diabetes and heart disease has found that every 2,000 steps they normally took each day was associated with a 10% lower risk of a cardiovascular event. And 12 months later, each extra 2,000 steps per day people did beyond their original number of steps was associated with an additional 8% difference in the cardiovascular event rate.
This large study recruited participants from around the world and the researchers adjusted for a number of potential confounders.
However, the study had a number of limitations, including:
A large amount of information on the number of s...
Source: NHS News Feed - December 23, 2013 Category: Consumer Health News Tags: Lifestyle/exercise Source Type: news
Effects of Valsartan Versus Amlodipine in Diabetic Hypertensive Patients With or Without Previous Cardiovascular Disease
In conclusion, the ARB- and the CCB-based treatments exerted similar protective effects of CVD events regardless of the presence of previous CVD. For stroke events, the ARB may have more protective effects than the CCB in diabetic hypertensive patients with previous CVD.
Source: The American Journal of Cardiology - September 16, 2013 Category: Cardiology Authors: Kentaro Yamashita, Takahisa Kondo, Takashi Muramatsu, Kunihiro Matsushita, Takanori Nagahiro, Kengo Maeda, Satoshi Shintani, Toyoaki Murohara Tags: Systemic Hypertension Source Type: research
Diabetics Taking Certain Blood Pressure Drugs At Lower Risk Of Heart Disease
Two drugs, telmisartan and valsartan, which are used to reduce blood pressure in people with diabetes, are associated with a lower risk of hospitalization for heart attack, stroke or heart failure, according to a study published in CMAJ (Canadian Medical Association Journal). For people with type 2 diabetes, disease-related vascular illnesses are the main causes of death. Angiotensin-receptor blockers including telmisartan, valsartan, candesartan, irbesartan and losartan, are generally used interchangeably to control blood pressure...
Source: Health News from Medical News Today - July 10, 2013 Category: Consumer Health News Tags: Hypertension Source Type: news
Two ARBs Lower Risk of CVD Complications in DiabeticsTwo ARBs Lower Risk of CVD Complications in Diabetics
Compared with irbesartan, the use of telmisartan and valsartan lowered the risk of hospital admission for MI, stroke, or heart failure by 15% and 14%, respectively. The reduction was driven primarily by a reduction in the risk of heart-failure hospitalizations. Heartwire
Source: Medscape Today Headlines - July 8, 2013 Category: Consumer Health News Tags: Cardiology News Source Type: news
Telmisartan, valsartan lower risk of CVD complications in diabetics
Compared with irbesartan, the use of telmisartan and valsartan lowered the risk of hospital admission for MI, stroke, or heart failure by 15% and 14%, respectively. The reduction was driven primarily by a reduction in the risk of heart-failure hospitalizations.
Source: theHeart.org - July 8, 2013 Category: Cardiology Source Type: news
Comparative effectiveness of angiotensin-receptor blockers for preventing macrovascular disease in patients with diabetes: a population-based cohort study.
We examined each outcome individually in secondary analyses, in addition to all-cause mortality. RESULTS:We identified 54 186 patients with diabetes who started taking an angiotensinreceptor blocker during the study period. After multivariable adjustment, patients who took either telmisartan (adjusted hazard ratio [HR] 0.85, 95% confidence interval [CI] 0.74-0.97) or valsartan (adjusted HR 0.86, 95% CI 0.77-0.95) had a lower risk of the composite outcome compared with patients who took irbesartan. In contrast, no significant difference in risk was seen between other angiotensin-receptor blockers and irbesartan. In secondar...
Source: cmaj - July 8, 2013 Category: Journals (General) Authors: Antoniou T, Camacho X, Yao Z, Gomes T, Juurlink DN, Mamdani MM Tags: CMAJ Source Type: research
